Kidney function may affect how HRS-1893 works in heart disease
NCT ID NCT06775834
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This completed Phase 1 study enrolled 24 adults aged 18-65, including people with mild or moderate kidney impairment and healthy volunteers. Researchers measured how the drug HRS-1893 moves through the body and is cleared, to help determine the right dose for patients with kidney problems. The study did not test the drug's effect on hypertrophic cardiomyopathy itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
Conditions
Explore the condition pages connected to this study.